WO2009118473A2 - Composés dérivés d'azétidines, leur préparation et leur application en thérapeutique - Google Patents
Composés dérivés d'azétidines, leur préparation et leur application en thérapeutique Download PDFInfo
- Publication number
- WO2009118473A2 WO2009118473A2 PCT/FR2009/000214 FR2009000214W WO2009118473A2 WO 2009118473 A2 WO2009118473 A2 WO 2009118473A2 FR 2009000214 W FR2009000214 W FR 2009000214W WO 2009118473 A2 WO2009118473 A2 WO 2009118473A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- phenyl
- azetidin
- bis
- chloro
- Prior art date
Links
- 0 CC*N(*)*=O Chemical compound CC*N(*)*=O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to azetidine derivatives, to their preparation and to their therapeutic application in the treatment or prevention of diseases involving cannabinoid CB 1 receptors.
- R represents a (C 1 -C 6 ) alkyl group, a halo (C 1 -C 6 ) alkyl group;
- R1 represents a hydrogen atom; a (C 1 -C 6 ) alkyl group;
- R2 is (Ci-C 6) alkyl substituted with one or more groups selected from hydroxy group, a (Ci-C 6) alkoxy, hydroxy (Ci-C 6) alkyl and optionally substituted with halo (Ci-C 6) alkyl; heterocycle group optionally substituted by one or more hydroxyls, a (C 1 -C 6 ) alkoxy group or a hydroxy (C 1 -C 6 ) alkyl group; heterocycle (C 1 -C 6 ) alkyl group optionally substituted with one or more hydroxyls; R3 and R4 each represent a phenyl group optionally substituted by one or more atoms or groups selected from hydrogen, halogen, (Ci-
- Y represents a hydrogen atom, a halogen, a (C 1 -C 6 ) alkyl group, an ImIo (C 1 -C 6 ) alkyl group, a (C 1 -C 6 ) aIcOXy group, a halo (C 1 - C 6 ) alkoxy, a (C 1 -C 6 ) alkylS (O) p or cyano group; p is from 0 to 2, in the form of a base or an addition salt with an acid.
- the compounds of formula (I) can comprise one or more asymmetric carbon atoms. They can therefore exist as enantiomers or diastereoisomers. These enantiomers, diastereoisomers, as well as their mixtures, including racemic mixtures, form part of the invention.
- s v ⁇ si Among the compounds of formula (I) which are subjects of the invention, a first group of compounds consists of compounds in a mixture of diastereoisomers and of enantiomers for which: R represents a methyl,
- R3 and R4 each represent a phenyl group substituted with a chlorine atom in the para position
- Y represents a hydrogen atom or a halogen or a group (dC 6 ) alkoxy or a halo (C r C 6 ) alkyl group
- R 1 represents a hydrogen atom
- R 2 represents a - (C 1 -C 6 ) alkyl group substituted with one or more groups selected from the group hydroxy, the group (QC 6 ) alkoxy, a hydroxy group (C 1 -C 6 ) alkyl and optionally substituted by a halo (C 1 -C 6 ) alkyl group; heterocycle group representing an oxetane, a tetrahydrofuran, a dioxolane, a tetrahydropyran optionally substituted with one or more hydroxy, hydroxymethyl; heterocycle (C 1 -C 6 ) alkyl group representing tetrahydrofurylmethyl, 2,2-dimethyl-
- a second group of compounds consists of compounds in a mixture of diastereoisomers and of enantiomers for which: R represents a methyl,
- R3 and R4 each represent a phenyl group substituted with a chlorine atom in the para position
- Y represents a hydrogen atom or a fluorine or an OMe group or a CF 3 group
- R 1 represents a hydrogen atom
- R 2 represents a (C 1 -C 6 ) alkyl group substituted by one or more groups chosen from the group hydroxy, the group (Ci-C 6) alkoxy, hydroxy (Ci-C 6) alkyl and optionally substituted with halo (Ci-C 6) alkyl: oxetane, tetrahydrofuran, dioxolane, tetrahydropyran optionally substituted by one or more hydroxy, hydroxymethyl; tetrahydrofurylmethyl, 2,2-dimethyl- [1,3] dioxolan-4-ylmethyl, [1,3] dioxolan-4-ylmethyl; in the form of a base or an acid addition salt.
- halogen a fluorine, a chlorine, a bromine or an iodine
- a (Ci-Q) alkyl group an aliphatic group comprising from 1 to 6 saturated, cyclic, branched or linear carbon atoms which may optionally be substituted with one or more linear, branched or cyclic (C 1 -C 6 ) alkyl groups.
- halo (Ci-C 6 ) alkyl group a (C 1 -C 6 ) alkyl group in which one or more hydrogen atoms have been substituted by a halogen atom.
- a hydroxy (C 1 -C 6 ) alkyl group a (C 1 -C 6 ) alkyl group in which one hydrogen atom has been substituted with one or more hydroxyls
- a (C 1 -C 6 ) alkoxy group a (C 1 -C 6 ) alkyl-O- group where the (C 1 -C 6 ) alkyl group is as previously defined
- a halo (Ci-Ce) alkoxy group a halo (C 1 -C 6 ) alkyl-O- group in which the halo (C 1 -C 6 ) alkyl group is as previously defined
- a heterocycle group is a monocyclic group comprising from 4 to 8 atoms, of which 1 to 3 oxygen atoms, this cyclic group is saturated or partially saturated.
- oxetane tetrahydrofuran, dioxolane and tetrahydropyran groups
- a heterocycle (C 1 -C 6 ) alkyl group is an alkyl group substituted with a heterocycle as defined above. Examples that may be mentioned include tetrahydrofuranyl-methyl, 2,2-dimethyl- [1,3] dioxolan-4-ylmethyl, [1,3] dioxolan-4-ylmethyl;
- the compounds of formula (I) may exist in the form of bases or salts. Such addition salts are part of the invention.
- salts can be prepared with pharmaceutically acceptable acids, but the salts of other acids that are useful, for example, for the purification or the isolation of the compounds of formula (I) are also part of the invention.
- the compounds of formula (I) may also exist in the form of hydrates or solvates, namely in the form of associations or combinations with one or more water molecules or with a solvent. Such hydrates and solvates are also part of the invention.
- the present invention also relates to the use of the compounds of the invention of formula (I) for the preparation of a medicament for the treatment or prevention of diseases in which the CB1 receptor is involved.
- the subject of the present invention is also the use of the compounds of the invention of formula (I) for the preparation of a medicament for the treatment or the prevention of psychiatric disorders, addiction and weaning to a substance, weaning smoking, cognitive disorders and attention and acute and chronic neurodegenerative diseases; metabolism, appetite disorders, appetite disorders, obesity, diabetes (type I and / or H), metabolic syndrome, dyslipidemia, sleep apnea; pain, neuropathic pain, neuropathic pain induced by anticancer drugs; gastrointestinal disorders, vomiting, ulcer, diarrhea, bladder and urinary disorders, endocrine disorders, cardio- vascular pressure, hypotension, hemorrhagic shock, septic shock, liver disease, chronic cirrhosis of the liver, fibrosis, non-alcoholic steatohepatitis (NASH), steatohepatitis and hepatic steatosis, regardless of the etiology of these conditions (alcohol, drug, chemical, autoimmune disease, obesity, diabetes, congenital
- the mesylation of compound 1 to derivative 2 can be carried out according to methods known to those skilled in the art or described in TW GREENE, Protective Group in Organic Synthesis, fourth edition. This reaction will be carried out in a chlorinated solvent such as dichloromethane in the presence of a base such as pyridine and a mesylate derivative such as mesyl chloride at a temperature of between -10 ° C. and 40 ° C.
- a chlorinated solvent such as dichloromethane
- a base such as pyridine
- mesylate derivative such as mesyl chloride
- R represents a protective group of the OH function of the acid.
- the derivative 4 is accessible by reaction of mesylate 2 with azetidine 3. This step is preferably carried out under an inert atmosphere, in an inert solvent such as 4-methyl-2-pentanone in the presence of a mineral base such as potassium carbonate at the reflux of the reaction mixture.
- an inert solvent such as 4-methyl-2-pentanone
- a mineral base such as potassium carbonate
- ester 4 to acid 5 is carried out according to methods known to those skilled in the art and, more specifically, in a mixture of polar solvents such as tetrahydrofuran and water in the presence of a base such as lithium hydroxide hydrated at a temperature in the region of 20 ° C.
- the formation of the compounds of formula (I) can be carried out by reaction between the acid 5 and an amine derivative 6.
- This reaction can be carried out in an inert solvent such as tetrahydrofuran, a chlorinated solvent (dichloromethane for example) , in the presence or absence of a base such as a trialkylamine (triethylamine for example), a coupling agent such as 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride or a supported carbodiimide, in the presence or absence of absence of an additive avoiding any racemization such as 1-hydroxybenzotriazole and in the presence or absence of an agent promoting peptide synthesis via the formation of a mixed anhydride such as risobutylchloroformate, at a temperature between -20 ° C. and the boiling temperature of the solvent.
- a mixed anhydride such as risobutylchloroformate
- the derivatives 6 are commercially available or synthesized, according to the methods known to those skilled in the art, from the appropriate commercial precursors.
- R2 represents a (Ci-C 6) alkyl substituted with one or more groups selected from hydroxy or the group (C r C 6) alkoxy
- these products can be obtained from products in which R2 is heterocycle (C 1 -C 6 ) alkyl group by deprotection of this group according to methods known to those skilled in the art and, more specifically, in an inert solvent such as tetrahydrofuran in the presence of an acid such as the acid 1N hydrochloric acid in diethyl ether at a temperature in the region of 20 ° C.
- the compounds of formula (I) can be purified by the usual known methods, for example by crystallization, chromatography or extraction.
- the enantiomers of the compounds of formula (I) can be obtained by resolution of the racemates, for example by chromatography on a chiral column according to PIRKLE WH et al., Asymmetric Synthesis, vol. 1, Academy Press (1983) or by salt formation or synthesis from chiral precursors.
- the diastereoisomers can be prepared according to known conventional methods (crystallization, chromatography or from chiral precursors).
- the present invention also relates to the process for preparing the intermediates.
- Example 1 3 - ( ⁇ 1 - [bis- (4-chloro-phenyl) -methyl] -azetidin-3-yl ⁇ -methanesulfonyl-amino) -N- (2,2-dimethyl-1,3-dioxol) 4-ylmethyl) -benzamide (Compound ⁇ ° 3)
- the dextrorotatory enantiomer was eluted in second position during the separation carried out in Example 2.
- concentration of the co-solvent 0.342 g of (+) - 3 - ( ⁇ 1- [bis- (4-chloro) phenyl) -methyl] -azetidin-3-yl ⁇ -methanesulfonylamino) -N- (2,2-dimethyl-1,3-dioxolan-4-ylmethyl) -benzamide as a white powder.
- the reaction medium is poured into an aqueous solution of sodium hydrogencarbonate. After decantation, the aqueous phase is extracted with ethyl acetate.
- N- (2,2-dimethyl-1,3-dioxolan-4-ylmethyl) -benzamide, 4 cm 3 of tetrahydrofuran and 2 cm 3 of a 1N hydrochloric acid solution in ethyl ether are stirred at a temperature of temperature close to 20 0 C for 5 hours.
- the reaction medium is poured into an aqueous solution of sodium hydrogencarbonate. After decantation, the aqueous phase is extracted with ethyl acetate.
- the organic phases are combined, washed with a saturated aqueous solution of sodium chloride, dried over magnesium sulphate, filtered and concentrated to dryness under reduced pressure (5 kPa).
- reaction medium is taken up in 40 cm 3 of dichloromethane and 10 cm 3 of a saturated aqueous sodium chloride solution. After decantation, the organic phase is dried over magnesium sulfate, filtered on sintered glass and then concentrated to dryness under reduced pressure to give 0.39 g of a meringue.
- the crude reaction product is purified by flash chromatography on a cartridge of 30 g of Merck silica (particle size: 15-40 ⁇ m, elution gradient: dichloromethane / methanol 98/2 to 95/5).
- the hydrochloride salt thus obtained undergoes the same treatment as above: stirring for 10 minutes in 0.7 cm 3 of dichloromethane and 0.1 cm 3 of a 2M hydrochloric acid solution in diethyl ether, concentration in vacuo, trituration twice with pentane, drying in an oven under vacuum at a temperature of 40 0 C for 2 hours 30 minutes. 99 mg of 3 - ( ⁇ 1- [bis- (4-chloro-phenyl) -methyl] -azetidin-3-yl ⁇ -methanesulfonyl-amino) -N- (2-hydroxyethyl) hydrochloride are thus obtained. benzamide as a yellowish meringue.
- Example 7 (-) - 3 - ( ⁇ 1- [bis- (4-Chloro-phenyl) -methyl] -azetidin-3-yl ⁇ -methanesulfonylamino) -N- (2-hydroxy-1-methyl); ethyl) -benzamide (Compound ⁇ ° 8)
- To a suspension of 0.5 g of 3 - [ ⁇ 1- [bis- (4-chloro-phenyl) -methyl] -azetidin-3-yl ⁇ -methylsulfonyl-amino] benzoic acid in 10 cm 3 of dichloromethane is 0.227 g of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride was added.
- the reaction medium is stirred at a temperature in the region of 20 ° C. for 20 hours and is then filtered on sintered glass by rinsing with dichloromethane. The filtrate is concentrated to dryness in vacuo to give 0.73 g of a white meringue which is purified by flash chromatography on a cartridge of 70 g of Merck silica (particle size: 15-40 ⁇ m, eluent: ethyl acetate / methanol 98/2).
- Table 1 which follows illustrates the chemical structures (I) and the physical properties (Table IA) of some examples of compounds according to the invention.
- Table 1 which follows illustrates the chemical structures (I) and the physical properties (Table IA) of some examples of compounds according to the invention.
- Table 1 which follows illustrates the chemical structures (I) and the physical properties (Table IA) of some examples of compounds according to the invention.
- Table 1 which follows illustrates the chemical structures (I) and the physical properties (Table IA) of some examples of compounds according to the invention.
- Table 1 which follows illustrates the chemical structures (I) and the physical properties (Table IA) of some examples of compounds according to the invention.
- Table 1 which follows illustrates the chemical structures (I) and the physical properties (Table IA) of some examples of compounds according to the invention.
- Table 1 which follows illustrates the chemical structures (I) and the physical properties (Table IA) of some examples of compounds according to the invention.
- Table 1 which follows illustrates the chemical structures (I) and the physical properties (Table IA)
- B represents the product obtained in base form.
- R3 and R4 each represent a phenyl group substituted with a chlorine atom in the para position
- the compounds according to the invention have been the subject of pharmacological tests making it possible to determine the activity with respect to human CB1 cannabinoid receptors.
- the effectiveness of the compounds of formula (I) was determined in a functional test measuring CB1 cannabinoid receptor activity (intracellular cyclic AMP test).
- the test for detection of intracellular cyclic AMP in U373MG cells expressing naturally the human CB1 receptor was carried out as described in the reference: Bouaboula et al., 1995, J. Biol. Chem. 270: 13973-13980.
- CisBio's hTRF cAMP Dynamic Kit was used for quantification of intracellular cyclic AMP.
- the IC 50 values are between 0.001 ⁇ M and 2 ⁇ M.
- Compounds Nos . 5, 7, 9, 18, 21, 26, 30, 36 and 47 have shown IC 50's respectively 0.022; 0.061; 0.015; 0.006; 0.038; 0.02; 0.066; 0.016 and 0.072 ⁇ M.
- Other tests consisting in measuring the in vivo activity of the compounds of the invention were carried out.
- a new measurement of the rectal temperature of the mice is performed and the racemic CP55,940 agonist (1RS, 3RS, 4RS-3- [hydroxy-2- (1,1-dimethylheptyl) phenyl] -4- ( 3-hydroxypropyl) cyclohexan-1-ol) (1.25 mg / kg ip in cremophor 10%) is administered.
- the rectal temperature is measured again. The results are expressed in% relative to the control batch injected with CP 55 940 (minimum temperature) and to the vehicle batch without treatment with CP55.940 (maximum temperature).
- Compounds Nos . 9 and 25 showed a percent inhibition of 30% and 18%, respectively, at 3 mg / kg / kg.
- CD1 male mice received the test product orally 30 minutes or 2 hours prior to administration of the racemic CP55,940 agonist (1RS, 3RS, 4RS-3- [hydroxy-2- (1,1- dimethylheptyl) phenyl] -4- (3-hydroxypropyl) cyclohexan-1-ol) (0.15 mg / kg ip in cremophore 10%).
- the animals receive a bolus of coal in.
- the animals are euthanized (CO 2 / O 2 ) and the intestine is dissected. The progression of the bolus of charcoal in the intestine is expressed as a percentage of the total length of the intestine.
- the compounds of the invention of formula (I) are CB1 cannabinoid receptor antagonists in vitro and in vivo. Some compounds are active in vivo on both the hypothermia and transit test, and some compounds show dissociated activities between the hypothermia and transit test.
- the compounds according to the invention can be used in the treatment or prevention of diseases involving CB 1 cannabinoid receptors.
- the compounds of formula (I) are useful as psychotropic drugs, especially for the treatment of psychiatric disorders including anxiety, depression, mood disorders, insomnia, delusional disorders , obsessive disorders, psychoses in general, schizophrenia, attention deficit hyperactivity disorder (ADHD) in hyperkinetic children (BDM) and for the treatment of disorders related to the use of psychotropic substances, including in the case of substance abuse and / or substance dependence, including alcohol dependence and nicotine addiction and withdrawal disorders.
- ADHD attention deficit hyperactivity disorder
- BDM hyperkinetic children
- the compounds of formula (I) according to the invention can be used as medicaments for the treatment of migraine, stress, psychosomatic diseases, panic attacks, epilepsy, movement disorders , especially dyskinesias or Parkinson's disease, tremors and dystonia.
- the compounds of formula (I) according to the invention can be used as medicaments for skin cancer and protection of the skin.
- the compounds of formula (I) according to the invention can also be used as medicaments in the treatment of memory disorders, cognitive disorders, in particular in the treatment of cognitive disorders related to senile dementia, to Alzheimer's disease, to schizophrenia and neurodegenerative diseases, as well as in the treatment of attention deficit or alertness disorders.
- the compounds of formula (I) may be useful as neuroprotective agents, in the treatment of ischemia, head trauma and the treatment of neurodegenerative diseases: including Huntington's chorea, Tourrette's syndrome.
- the compounds of formula (I) according to the invention can be used as medicaments in the treatment of pain: neuropathic pain, peripheral acute pain, chronic pain and pain of inflammatory origin.
- the compounds of formula (I) according to the invention can be used as medicaments in the treatment of appetite disorders, palatability (for sugars, carbohydrates, drugs, alcohols or any appetizing substance) and / or conduits. for the treatment of bulimia as well as for the treatment of type II diabetes or non-insulin-dependent diabetes and for the treatment of dyslipidemia, metabolic syndrome.
- the compounds of formula (I) according to the invention are useful in the treatment of obesity and the risks associated with obesity, in particular cardiovascular risks.
- the compounds of formula (I) according to the invention can be used as medicaments in the treatment of gastrointestinal disorders, diarrheal disorders, ulcers, vomiting, bladder and urinary disorders, endocrine, cardiovascular disorders, hypotension, hemorrhagic shock, septic shock, cirrhosis, hepatic fibrosis, steatohepatitis and hepatic steatosis, regardless of the etiology of these conditions: especially virus, alcohol, drug, chemical, autoimmune disease, obesity, diabetes, congenital metabolic disease, (hemochromatosis, alpha-1 antitrypsin deficiency, Wilson's disease, etc.), chronic cirrhosis of the liver, fibrosis, non-alcoholic steatohepatitis (NASH), asthma, chronic obstructive pulmonary disease, Raynaud, glaucoma, fertility disorders, inflammatory phenomena, inflammatory diseases, diseases of the immune system, especially autoimmune and neuroinflammatory such as rheumatoid arthritis, reactive
- the present invention relates to the use of a compound of formula (I), its pharmaceutically acceptable salts and their solvates or hydrates for the treatment of the disorders and diseases indicated above.
- the present invention relates to pharmaceutical compositions comprising, as active principle, a compound according to the invention.
- These pharmaceutical compositions contain an effective dose of at least one compound according to the invention, or a pharmaceutically acceptable salt, of said compound, as well as at least one pharmaceutically acceptable excipient.
- Said excipients are chosen according to the pharmaceutical form and the desired mode of administration, from the usual excipients which are known to those skilled in the art.
- compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, local, intratracheal, intranasal, transdermal or rectal administration the active ingredient of formula (I) above, or its salt, can be administered in unit dosage form, in admixture with conventional pharmaceutical excipients for the treatment of the disorders or diseases mentioned above.
- Suitable unit dosage forms include oral forms such as tablets, soft or hard capsules, powders, granules and oral solutions or suspensions, sublingual, oral, intratracheal, intraocular, intranasal forms of administration. by inhalation, topical, transdermal, subcutaneous, intramuscular or intravenous administration forms, rectal administration forms and implants.
- the compounds according to the invention can be used in creams, gels, ointments or lotions.
- a unitary form of administration of a compound according to the invention in tablet form may comprise the following components: Compound according to the invention 50.0 mg
- the dosage appropriate to each patient is determined by the physician according to the mode of administration, the weight and the response of said patient.
- the present invention also relates to a method of treatment of the pathologies indicated above which comprises the administration to a patient of an effective dose of a compound according to the invention, or of a pharmaceutically acceptable salt thereof.
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201071012A EA201071012A1 (ru) | 2008-02-29 | 2009-02-27 | Производные азетидинов, способ их получения и применение их в терапии |
AU2009229026A AU2009229026A1 (en) | 2008-02-29 | 2009-02-27 | Azetidine-derived compounds, preparation method therefor and therapeutic use of same |
MX2010009512A MX2010009512A (es) | 2008-02-29 | 2009-02-27 | Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica. |
CN2009801069919A CN101959855A (zh) | 2008-02-29 | 2009-02-27 | 氮杂环丁烷衍生化合物、其制备方法和其治疗用途 |
EP09724410A EP2254862A2 (fr) | 2008-02-29 | 2009-02-27 | Composés dérivés d'azétidines, leur préparation et leur application en thérapeutique |
BRPI0908336-7A BRPI0908336A2 (pt) | 2008-02-29 | 2009-02-27 | Compostos derivados de azetidinas, o respectivo preparo e a respectiva aplicação em terapêutica, medicamentos e composições farmacêuticas compreendendo os mesmos |
CA2716961A CA2716961A1 (fr) | 2008-02-29 | 2009-02-27 | Composes derives d'azetidines, leur preparation et leur application en therapeutique |
JP2010548143A JP2011513285A (ja) | 2008-02-29 | 2009-02-27 | アゼチジン誘導化合物、この調製方法および該化合物の治療的使用 |
IL207799A IL207799A0 (en) | 2008-02-29 | 2010-08-25 | Azetidine-derived compounds, preparation method therefor and therapeutic use of same |
US12/869,281 US20110053908A1 (en) | 2008-02-29 | 2010-08-26 | Azetidine-derived compounds, preparation method therefor and therapeutic use of same |
MA33175A MA32192B1 (fr) | 2008-02-29 | 2010-09-13 | Composés dérivés d'azétidines, leur préparation et leur application en thérapeutique |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR08/01117 | 2008-02-29 | ||
FR0801117A FR2928149B1 (fr) | 2008-02-29 | 2008-02-29 | Composes derives d'azetidines, leur preparation et leur application en therapeutique |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/869,281 Continuation US20110053908A1 (en) | 2008-02-29 | 2010-08-26 | Azetidine-derived compounds, preparation method therefor and therapeutic use of same |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009118473A2 true WO2009118473A2 (fr) | 2009-10-01 |
WO2009118473A3 WO2009118473A3 (fr) | 2009-11-19 |
Family
ID=39745128
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2009/000214 WO2009118473A2 (fr) | 2008-02-29 | 2009-02-27 | Composés dérivés d'azétidines, leur préparation et leur application en thérapeutique |
Country Status (20)
Country | Link |
---|---|
US (1) | US20110053908A1 (fr) |
EP (1) | EP2254862A2 (fr) |
JP (1) | JP2011513285A (fr) |
KR (1) | KR20100122489A (fr) |
CN (1) | CN101959855A (fr) |
AR (1) | AR070485A1 (fr) |
AU (1) | AU2009229026A1 (fr) |
BR (1) | BRPI0908336A2 (fr) |
CA (1) | CA2716961A1 (fr) |
CL (1) | CL2009000464A1 (fr) |
CO (1) | CO6251235A2 (fr) |
EA (1) | EA201071012A1 (fr) |
FR (1) | FR2928149B1 (fr) |
IL (1) | IL207799A0 (fr) |
MA (1) | MA32192B1 (fr) |
MX (1) | MX2010009512A (fr) |
PE (1) | PE20091431A1 (fr) |
TW (1) | TW200940503A (fr) |
UY (1) | UY31682A1 (fr) |
WO (1) | WO2009118473A2 (fr) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011107494A1 (fr) | 2010-03-03 | 2011-09-09 | Sanofi | Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation |
WO2011161030A1 (fr) | 2010-06-21 | 2011-12-29 | Sanofi | Dérivés de méthoxyphényle à substitution hétérocyclique par un groupe oxo, leur procédé de production et leur utilisation comme modulateurs du récepteur gpr40 |
WO2012004269A1 (fr) | 2010-07-05 | 2012-01-12 | Sanofi | Dérivés d'acide ( 2 -aryloxy -acétylamino) - phényl - propionique, procédé de production et utilisation comme médicament |
WO2012004270A1 (fr) | 2010-07-05 | 2012-01-12 | Sanofi | Dérivés 1,3-propanedioxyde à substitution spirocyclique, procédé de préparation et utilisation comme médicament |
WO2012010413A1 (fr) | 2010-07-05 | 2012-01-26 | Sanofi | Acides hydroxy-phényl-hexiniques substitués par aryloxy-alkylène, procédé de production et utilisation comme médicament |
WO2013037390A1 (fr) | 2011-09-12 | 2013-03-21 | Sanofi | Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase |
WO2013045413A1 (fr) | 2011-09-27 | 2013-04-04 | Sanofi | Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2934995B1 (fr) * | 2008-08-14 | 2010-08-27 | Sanofi Aventis | Composes d'azetidines polysubstitues, leur preparation et leur application en therapeutique |
KR101426408B1 (ko) * | 2013-02-19 | 2014-08-07 | 한국과학기술연구원 | 4각 고리 질소 화합물, 이를 포함하는 우울증, 정신 질환, 조루증, 또는 신경병증성 통증의 예방 또는 치료용 약학 조성물, 및 상기 약학 조성물을 포함하는 제제 |
GB201321601D0 (en) * | 2013-12-06 | 2014-01-22 | Canbex Therapeutics Ltd | Modulator |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001064634A1 (fr) | 2000-03-03 | 2001-09-07 | Aventis Pharma S.A. | Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation |
WO2003053431A2 (fr) | 2001-12-21 | 2003-07-03 | Aventis Pharma S.A. | Compositions pharmaceutiques a base de derives d'azetidine |
WO2005077897A1 (fr) | 2004-02-17 | 2005-08-25 | Laboratorios Del Dr. Esteve S.A. | Composes d'azetidine substitues, preparation et utilisation comme medicaments |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6479479B2 (en) * | 2000-03-03 | 2002-11-12 | Aventis Pharma S.A. | Azetidine derivatives, their preparation and pharmaceutical compositions containing them |
US6355631B1 (en) * | 2000-03-03 | 2002-03-12 | Aventis Pharma S.A. | Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation |
US6566356B2 (en) * | 2000-03-03 | 2003-05-20 | Aventis Pharma S.A. | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation |
US20030139386A1 (en) * | 2001-12-21 | 2003-07-24 | Sophie Cote | Pharmaceutical compositions based on azetidine derivatives |
-
2008
- 2008-02-29 FR FR0801117A patent/FR2928149B1/fr not_active Expired - Fee Related
-
2009
- 2009-02-26 TW TW098106237A patent/TW200940503A/zh unknown
- 2009-02-26 PE PE2009000286A patent/PE20091431A1/es not_active Application Discontinuation
- 2009-02-26 AR ARP090100656A patent/AR070485A1/es unknown
- 2009-02-27 EA EA201071012A patent/EA201071012A1/ru unknown
- 2009-02-27 KR KR1020107019131A patent/KR20100122489A/ko not_active Application Discontinuation
- 2009-02-27 WO PCT/FR2009/000214 patent/WO2009118473A2/fr active Application Filing
- 2009-02-27 CN CN2009801069919A patent/CN101959855A/zh active Pending
- 2009-02-27 MX MX2010009512A patent/MX2010009512A/es not_active Application Discontinuation
- 2009-02-27 CA CA2716961A patent/CA2716961A1/fr not_active Abandoned
- 2009-02-27 CL CL2009000464A patent/CL2009000464A1/es unknown
- 2009-02-27 UY UY031682A patent/UY31682A1/es not_active Application Discontinuation
- 2009-02-27 AU AU2009229026A patent/AU2009229026A1/en not_active Abandoned
- 2009-02-27 JP JP2010548143A patent/JP2011513285A/ja not_active Withdrawn
- 2009-02-27 BR BRPI0908336-7A patent/BRPI0908336A2/pt not_active IP Right Cessation
- 2009-02-27 EP EP09724410A patent/EP2254862A2/fr not_active Withdrawn
-
2010
- 2010-08-19 CO CO10102306A patent/CO6251235A2/es not_active Application Discontinuation
- 2010-08-25 IL IL207799A patent/IL207799A0/en unknown
- 2010-08-26 US US12/869,281 patent/US20110053908A1/en not_active Abandoned
- 2010-09-13 MA MA33175A patent/MA32192B1/fr unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001064634A1 (fr) | 2000-03-03 | 2001-09-07 | Aventis Pharma S.A. | Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation |
WO2003053431A2 (fr) | 2001-12-21 | 2003-07-03 | Aventis Pharma S.A. | Compositions pharmaceutiques a base de derives d'azetidine |
WO2005077897A1 (fr) | 2004-02-17 | 2005-08-25 | Laboratorios Del Dr. Esteve S.A. | Composes d'azetidine substitues, preparation et utilisation comme medicaments |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011107494A1 (fr) | 2010-03-03 | 2011-09-09 | Sanofi | Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation |
WO2011161030A1 (fr) | 2010-06-21 | 2011-12-29 | Sanofi | Dérivés de méthoxyphényle à substitution hétérocyclique par un groupe oxo, leur procédé de production et leur utilisation comme modulateurs du récepteur gpr40 |
WO2012004269A1 (fr) | 2010-07-05 | 2012-01-12 | Sanofi | Dérivés d'acide ( 2 -aryloxy -acétylamino) - phényl - propionique, procédé de production et utilisation comme médicament |
WO2012004270A1 (fr) | 2010-07-05 | 2012-01-12 | Sanofi | Dérivés 1,3-propanedioxyde à substitution spirocyclique, procédé de préparation et utilisation comme médicament |
WO2012010413A1 (fr) | 2010-07-05 | 2012-01-26 | Sanofi | Acides hydroxy-phényl-hexiniques substitués par aryloxy-alkylène, procédé de production et utilisation comme médicament |
WO2013037390A1 (fr) | 2011-09-12 | 2013-03-21 | Sanofi | Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase |
WO2013045413A1 (fr) | 2011-09-27 | 2013-04-04 | Sanofi | Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase |
Also Published As
Publication number | Publication date |
---|---|
KR20100122489A (ko) | 2010-11-22 |
EP2254862A2 (fr) | 2010-12-01 |
CN101959855A (zh) | 2011-01-26 |
CA2716961A1 (fr) | 2009-10-01 |
FR2928149A1 (fr) | 2009-09-04 |
EA201071012A1 (ru) | 2011-04-29 |
AR070485A1 (es) | 2010-04-07 |
US20110053908A1 (en) | 2011-03-03 |
AU2009229026A1 (en) | 2009-10-01 |
CL2009000464A1 (es) | 2010-04-09 |
MA32192B1 (fr) | 2011-04-01 |
WO2009118473A3 (fr) | 2009-11-19 |
MX2010009512A (es) | 2010-12-15 |
UY31682A1 (es) | 2009-09-30 |
JP2011513285A (ja) | 2011-04-28 |
CO6251235A2 (es) | 2011-02-21 |
IL207799A0 (en) | 2010-12-30 |
FR2928149B1 (fr) | 2011-01-14 |
BRPI0908336A2 (pt) | 2015-08-04 |
PE20091431A1 (es) | 2009-10-19 |
TW200940503A (en) | 2009-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009118473A2 (fr) | Composés dérivés d'azétidines, leur préparation et leur application en thérapeutique | |
EP1641763B1 (fr) | Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application comme antagonistes des recepteurs aux cannabinoides cb1 | |
EP1720837B1 (fr) | Derives de n-'(1,5-diphenyl-1h-pyrazol-3-yl)methyl sulfonamide avec une affinite pour les recepteurs cb1 | |
EP1720848B1 (fr) | Derives de alkylpiperazine- et alkylhomopiperazine- carboxylates, leur preparation et leur application en tant qu'inhibiteurs de l'enzyme faah | |
EP2430012B1 (fr) | Dérivés de 7-aza-spiro[3.5]nonane-7-carboxylates, leur prépraration et leur application en thérapeutique | |
EP1537096B1 (fr) | Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique | |
EP2344486B1 (fr) | Derives de carbamates d'alkylthiazoles, leur preparation et leur utilisation comme inhbiteurs de l'enzyme faah | |
FR2882054A1 (fr) | Derives de 1,5-diarylpyrrole, leur preparation et leur application en therapeutique | |
EP0702010A1 (fr) | Nouveaux dérivés du benzopyrane, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
FR2849032A1 (fr) | Derive de 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-n -(piperidin-1-yl)-1h-pyrazole-3-carboxamide, sa preparation, son application en therapeuthique | |
WO2010018328A1 (fr) | Composes d'azétidines polysubstitues, leur préparation et leur application en thérapeutique | |
EP1966173B1 (fr) | Derives heterocycliques, leur preparation et leur application en therapeutique. | |
EP2234966B1 (fr) | Derives d'azetidines, leur preparation et leur application en therapeutique | |
EP1966167B1 (fr) | Derives diaryltriazolmethylamine, leur preparation et leur application en therapeutique. | |
FR2887548A1 (fr) | Derives de 4,5-diarylpyrrole, leur preparation et leur application en therapeutique | |
FR2880023A1 (fr) | Derives de n-[(4,5-diphenyl-3-alkyl-2-thienyl) methyl] amine leur preparation et leur application en therapeutique | |
WO2010018329A1 (fr) | Composes polysubstitues d'azetidines, leur preparation et leur application en therapeutique | |
FR2888236A1 (fr) | Derives de n-[(1,5-diphenyl-1h-pyrazol-3-yl)methyl] sulfonamide, leur preparation et leur application en therapeutique | |
FR2876691A1 (fr) | Derives de pyridine, leur preparation, leur application en therapeutique | |
WO2010146299A1 (fr) | Esters derives d'azetidines, leur preparation et leur application en therapeutique comme modulateurs des recepteurs cannabinoides | |
EP2411383B1 (fr) | Derives de 3-alcoxy-4,5-diarylthiophene-2-carboxamide, leur preparation et leur application en therapeutique | |
FR2930941A1 (fr) | Derives d'azetidines, leur preparation et leur application en therapeutique | |
FR2925051A1 (fr) | Derives d'azetidines,leur preparation et leur application en therapeutique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980106991.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09724410 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009724410 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: DZP2010000487 Country of ref document: DZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3035/KOLNP/2010 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10102306 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 207799 Country of ref document: IL Ref document number: 12010501934 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2716961 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 20107019131 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010548143 Country of ref document: JP Ref document number: 587651 Country of ref document: NZ Ref document number: MX/A/2010/009512 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009229026 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: PI 2010004013 Country of ref document: MY |
|
ENP | Entry into the national phase |
Ref document number: 2009229026 Country of ref document: AU Date of ref document: 20090227 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201071012 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: PI0908336 Country of ref document: BR Kind code of ref document: A2 Effective date: 20100830 |